Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

of 2008 as compared to $114.3 million for the same period in 2007. Included in the $109.1 million of overall research and development spending is approximately $66.0 million of new investments in Nektar preclinical and clinical development programs.

Nektar reported a net loss for the quarter ended September 30, 2008 of $37.0 million or $0.40 per share, compared to a net loss of $18.6 million or $0.20 per share in the third quarter of 2007. For the first nine months of 2008, the company reported a net loss of $111.1 million or $1.20 per share, compared to a net loss of $71.8 million or $0.78 per share for the same period in 2007.

Conference Call to Discuss Third Quarter 2008 Financial Results

Nektar will host a conference call today for analysts and investors at 2:00 p.m. Pacific time to discuss the company's third quarter performance. This conference call will be available via webcast and can be accessed through a link that is posted on the Investor Relations section of the Nektar website, http://www.nektar.com. The web broadcast of the conference call will be available for replay through November 20, 2008.

To access the conference call, follow these instructions:

Dial: 866-362-4666 (U.S.); 617-597-5313 (international)

Participant Passcode: 63756947 (Howard Robin is the host)

Audio replay dial-in and passcode:

To access the replay, follow these instructions:

Dial: 888-286-8010 (U.S.); 617-801-6888 (international)

Participant Passcode: 41304675

Nektar to Host Annual R&D Day on November 12

Nektar will host its second annual R&D Day meeting on Wednesday, November 12, 2008 from 12:00 pm to 3:30 pm Eastern time at the InterContinental Hotel in New York City. For more information or to RSVP for this event, please visit the investor relations section of the company's website at http://www.nek
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Only weeks following the announcement that Henderson, Nevada ... a battery manufacturer create 29 well-paying jobs in Mojave ... launching in Henderson to deliver yet another win ... sector is going to build a stronger middle class ... works with small businesses that rely on middle class ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... VPP "STAR" DesignationBROOKS, Ore., April 15 Covanta ... (NYSE: CVA ) and a world ... scale Energy-from-Waste and other renewable energy projects, today ... status in the Oregon Department of Consumer and ...
... 15 A new series of national public service ... their health care by knowing and asking appropriate questions ... today by the U.S. Department of Health and Human ... Advertising Council and actress and health advocate Fran Drescher.The ...
... insomnia as a way to address pain, , , WEDNESDAY, April ... people with cancer has often led to trouble sleeping -- ... in fact, sleep seems to cause those problems rather than ... interventions such as cognitive behavioral therapy aimed at eliminating the ...
... The following is a statement by Joseph A. ... Addiction and Substance Abuse at Columbia University :Congratulations ... Carpenter-Palumbo, Commissioner of the New York State Office of ... Collaborative to Improve Outcomes for New York (ACTION) initiative ...
... NEW YORK, April 15 The impetus for the ... settlement by Quest Diagnostics Inc. was a "qui tam" ... the government revealed today. The qui tam lawsuit provided ... a Quest subsidiary, Nichols Institute Diagnostics Inc. (NID), manufactured ...
... go "Meatless" on MondaysNEW YORK, April 15 With World ... environmental advocates are calling on President Obama to take a ... of his predecessors in office have done. Watch the Meatless ... Roosevelt all instituted national meatless days in order to divert ...
Cached Medicine News:Health News:Covanta Marion Recognized for Health and Safety by Oregon OSHA 2Health News:Covanta Marion Recognized for Health and Safety by Oregon OSHA 3Health News:AHRQ and Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care 2Health News:AHRQ and Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care 3Health News:Businessman Exposed Problems With Quest Subsidiary's Blood Test Kits; Led to $302 Million Settlement 2Health News:Businessman Exposed Problems With Quest Subsidiary's Blood Test Kits; Led to $302 Million Settlement 3Health News:Obama Urged to Bring Back National Meatless Program 2
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... in the high dose groups achieved disease stabilization. ... ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), ... from its Phase 2 monotherapy clinical study of ... patients. In this monotherapy study 66% of patients ...
... STOCKHOLM, March 4 Diamyd Medical announces,today that the ... the,Diamyd(R) diabetes vaccine in children with high risk to ... http://www.newscom.com/cgi-bin/prnh/20080314/297194 ) , ... been one of,Diamyd Medical,s long term goals," says Elisabeth ...
Cached Medicine Technology:Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 2Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 3Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 4Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved 2
... The XL Advantage delivers higher magnification for ... crisp, true image, even at the highest ... edge clarity and precise color rendition is ... with an anti-reflective coating produce a superior ...
... delivers higher magnification for advanced surgical procedures. ... even at the highest magnification. 3.5x, 4.5x ... precise color rendition is ideal for surgical ... coating produce a superior image. The compact ...
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
... Prismatic loupes are higher ... guarenteeing edge to edge ... rendition., ,Keeler Prismatic loupes ... treated with anti reflective ...
Medicine Products: